Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 245

1.

Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin.

Gore M, Sadosky AB, Zlateva G, Clauw DJ.

Pain Pract. 2009 Sep-Oct;9(5):363-74. doi: 10.1111/j.1533-2500.2009.00292.x. Epub 2009 Jun 4.

2.

Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin.

Gore M, Tai KS, Zlateva G, Bala Chandran A, Leslie D.

Pain Pract. 2011 Nov-Dec;11(6):528-39. doi: 10.1111/j.1533-2500.2011.00450.x. Epub 2011 Mar 16.

PMID:
21435162
3.
4.

Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with fibromyalgia newly prescribed pregabalin or tricyclic antidepressants.

Gore M, Tai KS, Chandran A, Zlateva G, Leslie D.

J Med Econ. 2012;15(1):32-44. doi: 10.3111/13696998.2011.629263. Epub 2011 Oct 20.

PMID:
21970698
5.

Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care.

Gore M, Tai KS, Chandran A, Zlateva G, Leslie D.

J Med Econ. 2012;15(1):19-31. doi: 10.3111/13696998.2011.629262. Epub 2011 Oct 20.

PMID:
21970699
6.

Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy.

Udall M, Harnett J, Mardekian J.

J Med Econ. 2012;15(2):361-70. doi: 10.3111/13696998.2011.650773. Epub 2012 Jan 9.

PMID:
22181052
7.
8.

Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care.

Gore M, Zlateva G, Tai KS, Chandran AB, Leslie D.

Pain Pract. 2011 Mar-Apr;11(2):167-79. doi: 10.1111/j.1533-2500.2010.00415.x. Epub 2010 Aug 17.

PMID:
20723096
9.

Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain.

Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R, Planas-Comes A.

J Eval Clin Pract. 2012 Dec;18(6):1170-9. doi: 10.1111/j.1365-2753.2011.01752.x. Epub 2011 Aug 30.

PMID:
21883712
10.

Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.

Navarro A, Saldaña MT, Pérez C, Masramón X, Rejas J.

Pain Pract. 2012 Jun;12(5):382-93. doi: 10.1111/j.1533-2500.2011.00515.x. Epub 2011 Oct 18.

PMID:
22004531
11.
12.

Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin.

Kleinman NL, Sadosky A, Seid J, Martin RC, Labiner DM.

Epilepsy Res. 2012 Nov;102(1-2):13-22. doi: 10.1016/j.eplepsyres.2012.04.019. Epub 2012 May 14.

PMID:
22591752
13.

Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine.

Harnett J, Margolis J, Cao Z, Fowler R, Sanchez RJ, Mardekian J, Silverman SL.

Pain Pract. 2011 May-Jun;11(3):217-29. doi: 10.1111/j.1533-2500.2010.00440.x. Epub 2010 Dec 28.

PMID:
21199319
14.

Adding pregabalin or gabapentin for the management of community-treated patients with painful diabetic peripheral neuropathy: a comparative cost analysis.

Sicras A, Rejas J, Navarro R, Planas A.

Clin Drug Investig. 2013 Nov;33(11):825-35. doi: 10.1007/s40261-013-0131-8.

PMID:
24085589
15.

Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia.

Zhao Y, Sun P, Watson P, Mitchell B, Swindle R.

Pain Pract. 2011 May-Jun;11(3):204-16. doi: 10.1111/j.1533-2500.2010.00412.x. Epub 2010 Aug 27.

PMID:
20807351
16.

Health care costs in patients with fibromyalgia on pregabalin vs. duloxetine.

Burke JP, Sanchez RJ, Joshi AV, Cappelleri JC, Kulakodlu M, Halpern R.

Pain Pract. 2012 Jan;12(1):14-22. doi: 10.1111/j.1533-2500.2011.00470.x. Epub 2011 May 26.

PMID:
21615857
17.

Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.

Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, Ben-Joseph RH, Summers KH.

J Med Econ. 2010;13(3):482-91. doi: 10.3111/13696998.2010.506176.

PMID:
20684669
18.

Cost comparison of adding pregabalin or gabapentin for the first time to the therapy of patients with painful axial radiculopathy treated in Spain.

Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R, Planas-Comes A.

Clin Exp Rheumatol. 2013 May-Jun;31(3):372-81. Epub 2013 Feb 25.

PMID:
23432967
19.

Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population.

Udall M, Louder A, Suehs BT, Cappelleri JC, Joshi AV, Patel NC.

J Med Econ. 2013;16(6):784-92. doi: 10.3111/13696998.2013.793692. Epub 2013 Apr 26.

PMID:
23565813
20.

A systematic review of pharmacoeconomic studies for pregabalin.

Parker L, Huelin R, Khankhel Z, Wasiak R, Mould J.

Pain Pract. 2015 Jan;15(1):82-94. doi: 10.1111/papr.12193. Epub 2014 May 10. Review.

PMID:
24815038

Supplemental Content

Support Center